Brian Turpin, DO
The novel pan-TRK inhibitor larotrectinib (LOXO-101) achieved a 93% response rate in pediatric patients with TRK
fusion–positive solid tumors, according to findings from the phase I SCOUT trial presented at the AACR Special Conference on Pediatric Cancer.
The phase II portion of the SCOUT trial is now enrolling globally.
Turpin B, Albert CM, Mascarenhas L, et al. A pediatric phase 1 study of larotrectinib, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family: an updated analysis. Presented at: American Association for Cancer Research (AACR) Special Conference on Pediatric Cancer Research; December 3-6, 2017; Atlanta, Georgia.
... to read the full story